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Chapter One 
Introduction 
 
The human papillomavirus (HPV) is the established cause of virtually all cervical 
cancers (Bosch, Lorincz, Munoz, Meijer, & Shah, 2002) and costs the United States 
health system five billion dollars a year in direct medical costs (Insinga, Dasbach, & 
Elbasha, 2005).  In June 2006, the United States Food and Drug Administration (FDA) 
approved Gardasil® as the first vaccine available in the United States to help protect nine 
to 26 year old females from the significant health consequences of HPV (United States 
Food and Drug Administration, 2006).  The vaccine was later approved in 2009 for males 
of the same age (United States Food and Drug Administration, 2009b).  The vaccine 
protects against HPV-16 and HPV-18, which cause 70% of all cases of cervical cancer 
(Muñoz et al., 2003), and HPV-6 and HPV-11, which cause 90% of all cases of genital 
warts (Brown, Schroeder, Bryan, & Stoler, 1999; Greer et al., 1995; Lacey, Lowndes, & 
Shah, 2006).  An additional vaccine, Cervarix®, was approved for 10 to 26 year old 
females in October 2009 and protects against HPV-16 and HPV-18 (United States Food 
and Drug Administration, 2009a).  
Shortly after the FDA approved Gardasil® in 2006, the Center for Disease 
Control and Prevention Advisory Committee on Immunization Practices, or ACIP, voted 
to recommend the vaccine for all females starting at age 11 to 12 years old, with “catch-
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up” vaccination for all females 13 to 26 years old (Centers for Disease Control and 
Prevention, 2007).  The ACIP extended the same recommendation to Cervarix® (Centers 
for Disease Control and Prevention, 2010c) giving patients the option of routine HPV 
vaccination with either Cervarix® or Gardasil®.  The ACIP has not extended routine 
recommendation of HPV vaccination to males (Centers for Disease Control and 
Prevention, 2010d).  
Many professional organizations followed the lead of the ACIP in their own 
recommendations, including the American Medical Association, the American Academy 
of Pediatrics, the American College of Obstetricians and Gynecologists, the American 
Academy of Family Physicians, the Association of Women’s Health, Obstetric and 
Neonatal Nursing, the Society for Adolescent Medicine, the American College Health 
Association, as well as the American Cancer Society, supporting routine HPV 
vaccination for females.  Despite widespread support for the vaccine and high 
acceptability (55-100%) among adolescents, young adults, and parents of adolescents for 
HPV vaccination (Brewer & Fazekas, 2007), by the end of 2010, only 49% of females 
ages 13 to 17 had initiated the series and only 32% had received the full three doses 
required for full immunization (Centers for Disease Control and Prevention, 2011).  Even 
fewer young adult females ages 19 to 26 years old have started the series, with national 
estimates at 17% (Centers for Disease Control and Prevention, 2010a). 
To improve vaccination, opportunities for vaccine administration outside of 
traditional primary care offices should be considered (Schaffer et al., 2008).  
Reproductive health organizations such as Planned Parenthood often face unique 
challenges in their attempts to implement vaccination services, aiming to protect 
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populations at high risk for HPV, but struggling with the limited financial resources 
needed to carry out interventions that could improve vaccine uptake for their mostly 
uninsured patients.  Because of the significant influence of cost on HPV vaccine uptake, 
it may be necessary to identify areas to target resources that would improve vaccine 
uptake at the clinic encounter level.  In this introduction, I will provide background on 
HPV and the HPV vaccine, as well as present a conceptual framework intended to help 
understand the complexity of influences involved in vaccinating individuals.  
Background  
Health Relevance of HPV 
HPV infects more than six million people in the United States every year 
(National Cancer Institute, 2007).  The high prevalence of HPV makes it the most 
common sexually transmitted infection in the world.  In the United States, 25% of 14 to 
19 year old females, 45% of 20 to 24 year old females, and 27% of 25 to 29 year old 
females are infected with HPV (Dunne et al., 2007).  Despite its widespread prevalence, 
most individuals never realize they carry the virus.  It is often asymptomatic and in most 
individuals with an intact immune system, the immune response activated by the virus is 
enough to render it undetectable and without clinical manifestations of disease (Stanley, 
2006).  However, the virus persists in some individuals for unknown reasons and about 
10% of women experience its more serious health consequences, such as cervical cancer 
(Franco et al., 1999; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Molano et al., 2003; 
Moscicki et al., 1998; Richardson et al., 2003). 
More than 100 strains of HPV have been identified (Bernard et al., 2010).  Of 
those, 15 to 18 are considered “high-risk” strains causing cancer, 12 are considered “low-
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risk” strains causing genital warts, and the remaining strains have no identified health 
implications (Muñoz et al., 2003).  HPV is the necessary cause of virtually all cervical 
cancers (Bosch et al., 2002).  In addition, emerging data suggest that HPV is partially 
responsible for several other types of cancers, including vulvar and vaginal cancers in 
females, penile cancers in males, and anal, head and neck cancers in males and females 
(Centers for Disease Control and Prevention, 2009).  HPV also causes genital warts in 
males and females and rarely, recurrent respiratory papillomatosis (Centers for Disease 
Control and Prevention, 2009).  Females are disproportionately affected by HPV, as it 
causes more female specific cancers (cervix, vulva, vagina) than male specific cancers 
(penile).  Females in the United States experienced an estimated 3,900 vulvar cancers and 
2,300 vaginal cancers in 2010 (Jemal, Siegel, Xu, & Ward, 2010).  Despite the 
widespread availability of cervical cancer screening using the Papanicolau test, which 
detects precancerous cervical lesions caused by HPV and can result in early treatment 
and prevention of cervical cancer, an estimated 12,200 females developed cervical cancer 
in 2010, and 4,210 females died from it (Jemal et al., 2010).  This figure is more than ten 
times the estimated number of deaths (350) from testicular cancer in 2010 (Jemal et al., 
2010).     
A total of 5.6% of 18 to 59 year olds have experienced an outbreak of genital 
warts (Dinh, Sternberg, Dunne & Markowitz, 2008).  While genital warts do not have the 
potential to result in death the way cancer does, the visible genital lesions are difficult to 
treat, often requiring multiple treatment visits and costing an average of $291.36 per 
outbreak (Fine et al., 2007).  Without treatment, the warts can last for years, increasing 
the risk of transmission to others as well as potentially contributing to prolonged time 
  5 
periods of emotional suffering.  The psychological distress from the shame and stigma of 
genital warts can lead to a decreased quality of life for many individuals (Ireland, Reid, 
Powell, & Petrie, 2005; Jeynes, Chung, & Challenor, 2009; Mortensen & Larsen, 2010; 
Woodhall et al., 2008) 
The health consequences of HPV are costly.  The United States spends an 
estimated five billion dollars in direct medical costs annually on the prevention and 
treatment of HPV related disease, not including vaccination (Insinga et al., 2005).  
Widespread use of the HPV vaccine specifically is generally considered cost-effective at 
the population level if greater than 80% of females are vaccinated, according to a review 
of 12 cost-effectiveness modeling studies (Brisson, Van de Velde, & Boily, 2009).  With 
lower population levels of vaccination, the benefit of herd immunity diminishes, leaving 
the benefits of individual immunity only.  
Vaccine Background 
 The first HPV vaccine developed, Gardasil®, is manufactured using recombinant 
DNA technology.  The vaccine is formulated by extracting a piece of the L1 structural 
protein of HPV -6, -11, -16 and -18 to function as the antigen, which stimulates the 
production of antibodies by the host, and combining it with amorphous aluminum 
hydroxyphosphate sulfate as the adjuvant to boost the immune response.  The first dose 
provides immune protection greater than natural HPV infection, and the second and third 
doses help sustain the immune response over time (Villa et al., 2005).  At the time of 
FDA approval of Gardasil® in 2006, clinical trials demonstrated efficacy extending 
through five years post-vaccination (Villa et al., 2006).  Studies are ongoing to determine 
how long the protection will last beyond five years.  In 2006, the ACIP recommended 
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(Centers for Disease Control and Prevention, 2007) and continues to recommend (Centers 
for Disease Control and Prevention, 2010c), initiation of the vaccine in 11 to 12 year 
olds, an age young enough to increase the likelihood that the recipient is not yet sexually 
active and therefore HPV-naïve when the vaccine is most effective, but an age old 
enough to increase the likelihood that immunity will persist after the onset of sexual 
activity, when the recipient is most at risk.  The ACIP also recommends “catch-up” 
vaccination for all females through age 26 who did not receive the vaccine at age 11 to 12 
(Centers for Disease Control and Prevention, 2010c).  “Catch-up” vaccination was 
recommended because the vaccine was still found to be effective among individuals with 
previous exposure to HPV, as most (74%) of females were infected with only one HPV 
strain included in the vaccine, thereby remaining susceptible to protection from other 
strains of HPV included in the vaccine (Centers for Disease Control and Prevention, 
2007).   
According to the CDC Vaccine Price List, Gardasil® costs $130 per dose, plus 
vaccine administration costs, making it the most expensive vaccine of all routinely 
recommended pediatric and adult vaccines (Centers for Disease Control and Prevention, 
2010b).    
The evidence supporting Gardasil’s® safety profile is well documented through 
FDA pre-licensure clinical trials and post-licensure safety surveillance.  Because there are 
no live viruses used in the production of Gardasil®, it is not possible for the vaccine to 
cause infection in recipients.  According to the prescribing information 
(http://www.gardasil.com), possible side effects include syncope, headache, fever, 
nausea, dizziness, injection-site pain, swelling, erythema, pruritis and bruising.  Post-
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licensure safety surveillance through the Vaccine Adverse Event Reporting System 
(VAERS) continues to monitor adverse events following immunization (AEFIs) in the 
general public and has found most of Gardasil’s® reports of adverse events to be no 
greater than other vaccines (Slade et al., 2009).  With 23 million doses dispensed, 
VAERS did find an increase in reports of syncope (8.2 per 100,000), however it was later 
concluded that this effect was not specific to Gardasil®, but rather a common occurrence 
when vaccinating adolescents.  There are reports of venous thromboembolic events (e.g. 
deep vein thrombosis) (0.2 per 100,000 doses) in individuals receiving Gardasil®, 
although 90% of the 31 recipients with venous thromboembolic events had other known 
risk factors (Slade et al., 2009).  Of the 32 deaths reported, only four were unexplained by 
other causes (Slade et al., 2009).   
In October 2009, the FDA approved a second HPV vaccine, Cervarix®, which 
provides cervical cancer protection from HPV-16 and HPV-18 in females 10 to 25 years 
old (United States Food and Drug Administration, 2009a).  Cervarix® is similarly priced 
at $128 (Centers for Disease Control and Prevention, 2010b) and similarly effective, 
although does not provide the additional protection against genital warts that Gardasil® 
provides.  Also in October 2009, the FDA approved Gardasil® for use in males (United 
States Food and Drug Administration, 2009b), although the ACIP issued a permissive use 
recommendation (stating that Gardasil® may be given to males) but not recommending 
routine vaccination (in which all males would be vaccinated) at that time due to cost-
effectiveness concerns (Centers for Disease Control and Prevention, 2010d).  The 
difference in ACIP recommendations between males and females may have financial 
ramifications for individuals, as many insurance companies only provide cost coverage 
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for vaccines recommended by the ACIP.  Due to its earlier approval and availability, a 
majority of the research on HPV vaccine uptake in the United States at this time is 
limited to Gardasil® use in females, although the uptake of Cervarix® in females and 
Gardasil® in males will likely expand in the coming years. 
HPV Vaccine Uptake  
The 2010 National Immunization Survey-Teen provides a recent measurement of 
adolescent HPV vaccine uptake in the United States (Centers for Disease Control and 
Prevention, 2011).  In 2010, an average of 49% of adolescent females ages 13 to 17 years 
old had started the series and only 32% had completed it, an increase of 5% from 2009.  
Rhode Island boasts the highest vaccination rate in the country where 73% of adolescent 
females have begun the series, in sharp contrast to Idaho where only 29% of adolescent 
females have started the series.  In Michigan, the rates fall at the national average, where 
49% of adolescent females have received the first dose and 25% have completed the 
series. 
The 2009 National Health Interview Survey found that HPV vaccine initiation for 
18 to 26 year old females is significantly lower, at 17% (Centers for Disease Control and 
Prevention, 2010a).  This survey, as well as most other studies, focus on series initiation 
rather than series completion, due to the logistical burdens of longitudinal research.  
National Priorities 
Healthy People 2020 (http://www.healthypeople.gov) continues to identify HPV 
reduction as a national priority.  In the objectives, Healthy People 2020 includes the goal 
to, “Reduce the proportion of females with human papillomavirus (HPV) infection.”  To 
achieve the goal, it targets vaccinating 80% of adolescent females against HPV. 
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Conceptual Framework: Ecological Model of HPV Vaccine Uptake 
The research literature provides support for using an ecological model as a 
conceptual framework for understanding and researching HPV vaccine uptake.  First 
described by psychologist Urie Bronfenbrenner in 1979 and modified over the past 30 
years for use in many other disciplines and various populations, the ecological model 
recognizes that there are many levels of influence on an individual’s behavior 
(Bronfenbrenner, 1979).  Bronfenbrenner described his model as one of concentric 
circles, each circle, or level, influencing the circles, or levels, within.  The individual 
exists at the center of the circles.  Individual behavior is conceptualized as being 
influenced by the circles surrounding him or her.  One can easily adapt Bronfenbrenner’s 
model to the various levels of influence on HPV vaccine uptake, as described below (see 
Figure 1.1).  This dissertation uses the ecological framework to critically examine factors 
affecting HPV vaccine uptake at different levels.  
Public Policy 
As described in Chapter Two, public policy at both the federal and state levels, 
including federal funding and school immunization requirements, influence an 
individual’s vaccination status.  At the federal level, researchers in Australia were able to 
measure both the individual and population level effects after the country rapidly 
achieved 70% vaccination coverage in females in 2007 resulting from a national HPV 
vaccination policy (R. Lester and G. Whiteside, personal communication in Fairley et al., 
2009).  After years of increasing incidence of genital warts, the proportion of females 
with genital warts declined by 25% each quarter in 2008, and even unvaccinated, 
heterosexual males experienced a 5% reduction in genital warts during the same time 
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period, consistent with the concept that herd immunity in populations with large numbers 
of individuals vaccinated will provide secondary protection to unvaccinated individuals 
(Fairley et al., 2009).    
Similar results could be found in the United States.  Historically in the United 
States, national campaigns with financial commitments and school requirements at the 
state level have demonstrated effectiveness in reaching high vaccination rates against 
other infections, such as hepatitis B (Averhoff et al., 2004; Jacobs & Meyerhoff, 2004; 
Orenstein & Hinman, 1999; Wilson, Fishbein, Ellis, & Edlavitch, 2005).  In the case of 
HPV vaccination, despite a national recommendation by the ACIP for routine female 
vaccination and federal vaccine funding for underserved individuals, no states, except 
Virginia and Washington, DC, have enacted legislation to include HPV vaccination in 
their school entry requirements (see Chapter Two for further discussion on this topic).  
Absent widespread state mandated school entry requirements, the responsibility for 
vaccinating individuals has been passed to health care organizations. 
Health Care Organization  
As discussed in Chapter Three, there are many specific influences in health care 
organizations that can present as barriers or facilitators for individual vaccination.  These 
influences can range from insurance coverage to cost charged by the organization to the 
patient, to provider recommendation, as well as educational information provided by the 
health care organization regarding HPV risk or vaccine safety concerns.  Every individual 
is unique, often making it difficult for researchers to study the multi-level complex 
interactions that determine vaccine uptake, but understanding the broader system of 
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influences in HPV vaccine uptake should illuminate the search for solutions to determine 
which interventions would have the greatest impact. 
Statement of Overall Problem Addressed in the Research 
The health and economic consequences of HPV are severe and prevention 
through HPV vaccination can significantly reduce them.  However, uptake of this 
potentially lifesaving vaccine remains low.  Examining influences at the public policy 
level (Chapter Two) and the health care organization level (Chapter Three) supports at 
this time exploration into possible vaccine interventions for health care organizations.  In 
organizations with high-risk patients but limited financial resources, targeting vaccination 
(Chapter Four) to reduce cost may be one possibility to improve uptake.  
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Figure 1.1.  Ecological model of HPV vaccine uptake. 
Public	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Chapter Two 
How Gardasil’s®  Policy History Influences A Patient’s Vaccination Status 
 
HPV causes a variety of serious health problems, including cervical, vulvar, 
vaginal, anal, penile, and head and neck cancers, as well as genital warts, and recurrent 
respiratory papillomatosis (Centers for Disease Control and Prevention, 2009c).  Passed 
through sexual contact, HPV infects 45% of all 20 to 24 year old females (Dunne et al., 
2007) and an estimated 80% of all individuals will contract HPV in their lifetime (Myers, 
McCrory, Nanda, Bastian, & Matchar, 2000).  In June 2006, the United States Food and 
Drug Administration (FDA) approved Gardasil®, the first vaccine to help protect against 
cervical cancer and genital warts caused by HPV (United States Food and Drug 
Administration, 2006).  However, in the United States only 49% of adolescent females 
ages 13 to 17 years old have started the recommended three dose series and only 32% 
have completed the series (Centers for Disease Control and Prevention, 2011).   
This chapter will provide an illustrative exploration into Gardasil’s® policy 
history at the federal, state, and health care organization level.  Policy history at the 
federal level includes the FDA approval of Gardasil®, the Advisory Committee on 
Immunization Practices’ (ACIP) HPV vaccine recommendation, and the Vaccines for 
Children (VFC) funding of the HPV vaccine.  Because federal public policy defers to 
states for implementation and management of vaccine programs, this chapter will next 
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describe state attempts at legislating vaccination policies to include Gardasil® in school 
entry requirements, using the examples of the unsuccessful attempt in Texas and the 
successful legislation in Virginia and Washington, DC.  Because most states have not 
passed legislation to include HPV vaccines in school entry requirements, health care 
organizations have been left to improve vaccination rates of individual patients.  
Therefore, the chapter next presents an example of one organization’s struggle to 
vaccinate its patients to illuminate the influence of the federal and state policies on health 
care organizations and ultimately, individuals.  Finally, this paper will look toward the 
future at the potential influence of the Affordable Care Act on HPV vaccine uptake.  
Federal Policy:  Approval, Recommendation, and Funding 
Approval:  FDA  
In June 2006 after an expedited review of data presented by Merck & Co. of 
clinical trials involving 29,000 participants, the FDA approved Gardasil® for the 
prevention of cervical cancer and genital warts in females ages nine to 26 years old 
(United States Food and Drug Administration, 2006).  With the emergence of new data, 
the FDA expanded the indication of Gardasil® in September 2008 to include the 
prevention of vulvar and vaginal cancers (United States Food and Drug Administration, 
2008) and in October 2009, the FDA approved Gardasil® for the prevention of genital 
warts in males ages nine to 26 years old (United States Food and Drug Administration, 
2009b).   
Gardasil® protects against four of the most common strains of HPV, which cause 
90% of all cases of genital warts (Brown, Schroeder, Bryan, & Stoler, 1999; Greer et al., 
1995; Lacey, Lowndes, & Shah, 2006) and 70% of all cases of cervical cancer (Muñoz et 
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al., 2003).  Gardasil® requires three shots given over six months at a cost of $360 per 
person, not including vaccine administration fees (Centers for Disease Control and 
Prevention, 2009b).  By May 2010, Merck & Co. had distributed 29.5 million doses of 
Gardasil® in the United States, making Gardasil® a highly profitable product in addition 
to a highly effective vaccine (Centers for Disease Control and Prevention, 2010). 
Until recently, Gardasil® was the only HPV vaccine available in the United 
States.  A second HPV vaccine, Cervarix®, was approved by the FDA in October 2009 
for use in females ages 10 to 25 (United States Food and Drug Administration, 2009a).  
Cervarix® protects against the two common strains of HPV causing cervical cancer, and 
has been approved for the prevention of cervical cancer.  Because of its recent 
availability and limited market share, Cervarix® has not yet substantially influenced 
HPV vaccination policy in the United States as it has in other countries, such as the 
United Kingdom.  
Recommendation:  Advisory Committee on Immunization Practices 
Once the FDA approves a vaccine based on safety and efficacy, the Advisory 
Committee on Immunization Practices (ACIP) is charged with the task of establishing 
vaccine recommendations.  Consisting of 15 immunization experts appointed by the 
Secretary of the U.S. Department of Health and Human Services, the overall goal of the 
ACIP is to “provide advice that will lead to a reduction in the incidence of vaccine 
preventable diseases in the United States, and an increase in the safe use of vaccines and 
related biological products” (Centers for Disease Control and Prevention, 2009a).  The 
group meets three times each year to evaluate available evidence and update 
immunization recommendations.   
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At the ACIP meeting in Atlanta in June 2006, the group finalized their 
recommendation for Gardasil®, which had been approved by the FDA earlier in the 
month.  The committee evaluated extensive clinical trial safety and efficacy data, plans 
for post marketing surveillance, and studies modeling cost-effectiveness.  After a public 
comment session at which not a single individual or group offered opposition, the group 
voted 13 to 0 (with two abstentions due to conflicts of interest) in favor of routine 
recommendation for all females ages nine to 26 years old (Advisory Committee on 
Immunization Practices, 2006).  A few years later, in October 2009, it voted 12 to one in 
favor of a permissive recommendation for Gardasil® for males, stating that the 
“Quadrivalent HPV vaccine may be given to males…to reduce their likelihood of 
acquiring genital warts” (Advisory Committee on Immunization Practices, 2009, p. 53).  
The ACIP was unable to support for males the routine recommendation it provided to 
females due to cost-effectiveness concerns.   
While the ACIP recommendations emerged as straightforward and scientifically 
supported, the ACIP could not escape the appearance of a possible conservative Christian 
influence not found in other vaccines.  Interesting to note in the ACIP group was the 
inclusion of Reginald Finger, MD who concluded his term as a member of the ACIP at 
the meeting in which the ACIP established the recommendation for Gardasil®.  Dr. 
Finger’s appointment to the ACIP by the Bush administration concerned many HPV 
vaccine supporters who feared his work as a medical issues analyst for the conservative 
Christian organization Focus on the Family, would compel him to put faith ahead of 
scientific objectivity.  In fact, his own website acknowledges that “In everything I do, I 
seek to put Jesus Christ and His kingdom first” (Finger, 2011a).  Dr. Finger’s 
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appointment was seen as part of a larger political strategy to support a conservative 
Christian agenda.  According to James A. Monroe, Jr., a political science professor at 
Brown University, “What the Bush administration has done has taken this coterie of 
people and put them into very influential positions in Washington.  And it’s having an 
effect in debates like this” (Stein, 2005).   
Dr. Finger did give vaccine supporters reason to be concerned.  He told The 
Washington Post, “There are people who sense that it [Gardasil®] could cause people to 
feel like sexual behaviors are safer if they are vaccinated and may lead to more sexual 
behavior because they feel safe” (Stein, 2005), raising concerns in the minds of the public 
about adolescent female sexual disinhibition.  The comments may have been taken out of 
context, as he made the comments fully realizing and subsequently acknowledging that 
the concerns were unfounded.  
I and others pointed out on several occasions that the issue of "disinhibition" - 
the impact on sexual behavior that can result when a sexually transmitted disease  
becomes preventable or more easily treatable - should be considered and thought  
through with regard to HPV.  Experts at CDC have studied the issue and have  
concluded that disinhibition is not a significant factor with HPV and should not be  
a reason to avoid the vaccine. I have consistently agreed with this conclusion  
(Finger, 2011b).  
Focus on the Family and other conservative Christian organizations, initially 
uncomfortable with the idea of a vaccine protecting against a sexually transmitted 
infection that can only be acquired outside of their abstinence doctrine, also quickly 
recognized the importance of supporting a vaccine that prevents cancer for the sake of 
public relations (Gold, 2007).  However, the groups continued to provide conflicting 
messages in which they implied that HPV was a punishment for ignoring their abstinence 
only message despite their support for the vaccine.  Focus on the Family’s Linda 
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Klepacki was quoted in a New York Times article stating, “You can’t catch the virus.  
You have to go out and get it with sexual behavior.  We can prevent it by having the best 
public health method, and that’s not having sex before marriage” (Harris, 2006).  
Merck & Co. recognized the potentially devastating effects that comments by Dr. 
Finger and conservative Christian organizations could have on public support for the 
vaccine, and the possible threat that Dr. Finger’s religious affiliation could have on his 
vote in the ACIP.  Merck & Co. began lobbying Focus on the Family and Dr. Finger 
directly.  Whether Merck & Co.’s lobbying efforts determined the organization’s 
position, or if public opinion or scientific evidence was more influential, is unclear.  
Ultimately, the mission of Focus on the Family, “To cooperate with the Holy Spirit in 
sharing the Gospel of Jesus Christ with as many people as possible” (Focus on the 
Family, 2009) proved to be compatible with preventing the sharing of HPV.  The Vice 
President for Policy at the Family Research Council, another conservative Christian 
organization, in an editorial in the Washington Post at the time of the ACIP 
recommendation, clarified the reconciliation of his organization’s abstinence-only 
message with its pro-vaccine position by writing,  
Behavioral self-restraint and vaccination are not mutually exclusive, since even 
someone who practices abstinence and fidelity could be exposed to HPV through 
sexual assault or marriage to an infected partner.  But, as with other public health 
issues such as smoking, we should not limit ourselves to risk-reduction strategies 
when risk elimination is the ultimate goal (Sprigg, 2006).  
 
In the end, Focus on the Family and other conservative Christian organizations publicly 
supported the HPV vaccine and Dr. Finger voted with the rest of the ACIP in its 
recommendations. 
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Many professional organizations followed the lead of the ACIP in their own 
recommendations, including the American Medical Association, the American Academy 
of Pediatrics, the American College of Obstetricians and Gynecologists, the Association 
of Women’s Health, Obstetric and Neonatal Nurses, the American Academy of Family 
Physicians, the Society for Adolescent Medicine, and the American College Health 
Association, supporting routine HPV vaccination for females.  The agreement of 
professional organizations with the ACIP’s recommendations strengthened the likelihood 
of HPV vaccine uptake in the population, as a provider’s professional organization 
recommendation is strongly associated with a provider’s willingness to recommend the 
vaccine to patients (Raley, Followwill, Zimet, & Ault, 2004; Riedesel et al., 2005) and a 
provider’s recommendation of the HPV vaccine is significantly associated with a patient 
receiving the vaccine (Dempsey, Abraham, Dalton, & Ruffin, 2009; Jain et al., 2009; 
Reiter, Brewer, Gottlieb, McRee, & Smith, 2009).    
Funding:  Vaccines For Children  
After the FDA approved Gardasil®, and the ACIP established the 
recommendations for Gardasil®, the final federal policy contribution included funding 
Gardasil® through the Vaccines for Children (VFC) program, a federal program that 
pays for nearly half of all childhood vaccines provided in the United States.  While the 
ACIP’s recommendation clearly had a strong influence in establishing guidelines for 
HPV vaccination and winning the healthcare community’s support for the HPV vaccine, 
it also had an important impact on making Gardasil® financially feasible for many 
individuals by voting to include Gardasil®, as it has with all other recommended 
vaccines, in the VFC program. 
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 The VFC program has been funding vaccines for specific populations in the 
United States since the 1990s.  On October 1, 1994, the Omnibus Budget Reconciliation 
Act of 1993 established the VFC program with the purpose of providing free vaccines to 
children through age 18 who may otherwise be unable to afford them.  Initially proposed 
as the Childhood Immunization Initiative, the program was a sweeping solution to the 
resurgence of measles due to low vaccination rates (Centers for Disease Control and 
Prevention, 1994).  Caught up in the short-lived enthusiasm for universal health care 
under the Clinton Administration, the Childhood Immunization Initiative would have 
provided recommended vaccines to all children regardless of income, streamlining the 
delivery of vaccines for all providers and eliminating cost concerns for all recipients.  
Had the Childhood Immunization Initiative succeeded, providers today may have enjoyed 
a single source of free vaccines for all patients rather than having to manage multiple 
sources of vaccines and the multiple ordering, storage, eligibility and billing requirements 
that accompany a fragmented delivery system.   
Instead of the universal vaccination program envisioned under the Childhood 
Immunization Initiative, the more restrictive VFC program was passed as an entitlement 
program under Medicaid.  The VFC program is limited to specific populations, including 
children who are Medicaid eligible, American Indian, Alaska Native, uninsured, or 
underinsured.  The reasoning was sound- have private insurance companies pay for 
vaccines for their own enrollees to reduce the cost to the federal government and the 
federal government would pay for vaccines for those children not covered by private 
insurance.  Unfortunately, the intended effect of universal vaccination was diminished by 
the unintended complexity of implementation.  
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The federal government funds the VFC program and requires that certain 
children, including those with Medicaid, be eligible for participation, but leaves 
administration of the program to the individual states.  The federal funds pass from the 
Office of Management and Budget through the Centers for Medicare and Medicaid 
Services to the Centers for Disease Control and Prevention (CDC).  The CDC then 
purchases vaccines at a reduced rate and the funds, now in the form of vaccines, resume 
their journey from the CDC to the states, usually through the state health departments 
who send it on to VFC providers. 
Individual states vary in their establishment of child and provider eligibility for 
VFC participation.  Some restrictive states limit private providers to using VFC vaccines 
for certain VFC eligible children, such as Medicaid eligible children, but require 
providers to send other VFC eligible children, such as underinsured children, to state 
health departments for VFC vaccines.  Mississippi, with one of the lowest HPV 
vaccination rates in the country, uses this type of restrictive policy.  Less restrictive states 
add their own vaccines to the VFC supply and provide vaccines to public and private 
providers for vaccination of all children, regardless of VFC eligibility.  New Hampshire, 
a state with one of the highest HPV vaccination rates in the country, utilizes this universal 
VFC policy.  The variation of VFC policies among states is extensive within these two 
extremes, including policies requiring a VFC provider to carry all recommended 
vaccines, or other policies that prohibit Medicaid reimbursement for a recommended 
vaccine (requiring that the Medicaid patient receive VFC funded vaccine from a VFC 
provider), making vaccination complex, confusing, and vulnerable to inequities. 
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In addition to the complexity of VFC funding and administration, Section 317 of 
the Public Health Services Act provides grants for states to support the cost of 
immunizations and reduce vaccine preventable illness.  Like VFC, Section 317 funds are 
intended to provide support for groups without a means of paying for vaccines and are 
administered by states and therefore subject to significant variation for individuals based 
on residency and budget shifts.  Unlike VFC funds though, they are often used for 
individuals with insurance but without immunization coverage specifically, and may be 
used for adult vaccination.  While not a comprehensive solution to the cost of 
immunization, Section 317 funds are yet another contribution at the federal policy level 
that may be used to support HPV vaccine uptake, intended to provide some support for 
improving vaccination and decreasing disease in the United States.    
In conclusion, federal public policy influenced Gardasil® through three 
mechanisms.  First, the FDA approved the vaccine for the prevention of cervical cancer 
and genital warts, and later vulvar and vaginal cancers.  Next, the ACIP recommended 
Gardasil® for all females age nine to 26 years old.  Finally, the ACIP voted to include 
Gardasil® in the VFC program to provide federal funding for Gardasil® vaccination.  
The next level of policy influence was at the state level, specifically vaccine school entry 
requirement legislation.  
State Policy:  School Entry Requirements 
 After June 2006, with the federal policy decisions established including FDA 
approval, the ACIP recommendation, and VFC funding, the states were left to establish 
their own HPV vaccination policies while riding a wave of public support.  According to 
the National Conference of State Legislatures, 41 states and the District of Columbia 
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have introduced some type of HPV vaccine legislation and 19 states have passed 
legislation involving HPV vaccination since Gardasil® was approved in 2006.  While 
most states are addressing HPV vaccination policy, the type of legislation varies 
significantly in scope and outcome from state to state, including legislation ranging from 
education to funding to school entry requirements (National Conference of State 
Legislatures, 2010).    
While HPV vaccination education may be a publicly acceptable form of 
legislation to support, vaccinating a large population often requires a more active 
approach.  One of the most effective ways to achieve high vaccination rates in general is 
through the inclusion of vaccines in school entry requirements (Averhoff et al., 2004; 
Jacobs & Meyerhoff, 2004; Orenstein & Hinman, 1999).   
…school laws establish a system for immunization, a system that works year in  
and year out, regardless of political interest, media coverage, changing budget  
situations, and the absence of vaccine-preventable disease outbreaks to spur  
interest (Orenstein & Hinman, 1999, p. S23).   
 
The challenge, of course, is passing legislation.  In the United States, the efficacy 
of the intervention in achieving the desired outcome is often overshadowed as the debate 
transforms into one of parental rights and individual freedoms.  Satisfying the variety of 
stakeholders- including state health departments, state-based professional organizations, 
medical societies, legislators, citizens, vaccine manufacturers, parents organizations, and 
insurance companies- while dealing with cost issues, the media, anecdotal stories and 
politics can turn the process into an enormous challenge (Horlick, Shaw, Gorji, Fishbein, 
& Working Group on Legislation, Vaccination and Adolescent Health, 2008).  
Furthermore, as school entry requirements are increasingly referred to as controversial, 
public support for HPV vaccine inclusion in school entry requirements decreases 
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(Gollust, Dempsey, Lantz, Ubel, & Fowler, 2010).  The following two sections provide 
case examples of two different state approaches to HPV vaccination and school entry 
requirements. 
Texas:  The Case of Executive Order Backlash 
 Texas became the first state in the country to pass a school entry requirement for 
the HPV vaccine, an achievement that quickly backfired.  On February 2, 2007, less than 
a year after the HPV vaccine was approved by the FDA and recommended by the ACIP, 
the Republican governor Rick Perry signed an executive order to require the HPV 
vaccine for all sixth grade girls.  Governor Perry proposed to begin the policy in 
September 2008, a policy that included a provision to allow parents to easily decline 
vaccination.  Bypassing the state legislature relieved representatives from having to take 
a public position on HPV vaccination and school entry requirements, a position they 
recognized as being potentially politically controversial due to the sexual transmission of 
HPV.  Supporters of the executive order hailed it as triumph for women’s health.  The 
president of the advocacy group The Texas Freedom Network remarked,  
Today’s decision by the governor is not just a positive step forward in efforts to  
promote women’s health.  It is also an important acknowledgement that health  
and science should not be held hostage to politics and ideology (Blumenthal,  
2007a).  
  
In an interesting twist, the attempted removal of politics and ideology from 
science and health through the use of the executive order may have resulted in the 
infusion of politics and ideology back into the issue.  Within days of the executive order, 
fellow Republicans introduced legislation to stop the executive order.  A group of parents 
from Dallas swiftly sued the governor to prevent the executive order from taking effect, 
claiming the order conflicted with the state’s abstinence only sex education policies.  
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Questions and suspicions began to arise when it was revealed that the governor’s former 
chief of staff began a new position as a Merck & Co. lobbyist.  By April 25, less than two 
months after the executive order was signed, the House passed HB1098 with a vote of 
135 to 2 to override the executive order.  The governor chose not to veto the bill, thus 
ending the country’s first school entry requirement for the HPV vaccine.  
The political reasons for the executive override overshadowed the health benefit 
for women, a risk for any public health issue decided by politicians instead of health care 
professionals.  “This kind of imperiousness [the executive order] offended his base” 
according to one political analyst (Blumenthal, 2007b), indicating that a personal political 
offense took precedence over the politician’s public policy responsibilities to pass 
effective legislation.  In a commonly cited concern for individual rights over public 
health benefits, contrary to the evidence based ACIP recommendation for routine 
vaccination, one state representative commented,  
We believe that parents and doctors should make an informed decision based on  
their daughters’ specific personal situation.  By no means am I or the members  
who voted for this bill saying that parents with their own choosing should not give  
this vaccination to their child (Frosch, 2007).   
 
The effect, however, was that the high vaccination rates school entry requirements 
produce, and the population-wide public health benefits that result, became less likely to 
occur.  While parents could easily choose to not vaccinate their daughters under the 
executive order, the loss of availability and financial accessibility afforded to school 
vaccines meant that instead many parents would not easily choose to vaccinate their 
daughters.    
 A unique contribution to the failure of Texas’s executive order, and perhaps 
school entry legislation in other states, was ultimately Merck & Co. itself.  Merck & Co. 
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recognized the enormous profits to be gained through widespread use of its vaccine.  
With the FDA approval of Gardasil®, Merck & Co. began an intensive and expensive 
direct-to-consumer advertising campaign, a common practice that earned the 2008 
Pharmaceutical Advertising and Marketing Excellence award and Pharma Executive 
Magazine’s brand of the year.  Their campaign did not stop with consumers.  They 
provided educational grants to professional medical associations, also a common practice, 
including the American College of Obstetricians and Gynecologists, the American 
College Health Association, the American Society for Colposcopy and Cervical 
Pathology, and the Society of Gynecologic Oncologists to promote Gardasil® (Rothman 
& Rothman, 2009).  While many new products undergo direct-to-consumer advertising 
and provide educational grants for professionals, Merck & Co. also began funding intense 
lobbying efforts for school entry requirements for Gardasil®, which was not a common 
practice.  The lobbying efforts included contributions to the bi-partisan, non-profit group 
of state legislators, Women in Government, in an effort to establish school entry 
requirements as a reliable source of long-term vaccine sales, as well as contributions to 
Governor Rick Perry’s campaign.    
Merck & Co.’s lobbying campaign initially appeared successful.  By February 
2007, when the Texas governor signed his executive order, 20 states were considering 
legislation to include the HPV vaccine in school entry requirements.  However, around 
that time, the public began hearing stories of Merck & Co.’s funding of state lobbying 
efforts for school entry requirements and its contribution to Governor Rick Perry’s 
campaign.  People began to question the ethics of this type of lobbying activity.  As the 
  34 
public backlash began to emerge, Merck & Co. recognized the potential political harm of 
such intense lobbying and ceased funding the effort. 
With the passing of time, Merck & Co.’s lobbying efforts were no longer 
considered influential.  In a study of key informants across the United States involved in 
legislating the HPV vaccine, conducted between 2008 and 2009, the newness of the 
vaccine and the cost of the vaccine were both cited as influential factors in the legislative 
decisions in Texas (Colgrove, Abiola, & Mello, 2010).  These more practical concerns, 
however, were not the focus of the public debate in 2007.  
After a five year “softening up” period, the heated battle opposing required HPV 
vaccination has cooled to indifference- perhaps a move in the direction of acceptance.  
Texas Rep. Jessica Farrar, who voted against the executive order in 2007, introduced HB 
2220 in March 2009, which would give the Executive Commissioner of the Health and 
Human Services Commission the authority to require HPV vaccination.  The bill 
continues to languish in committee (National Conference of State Legislatures, 2010).  
Meanwhile, Texas’ HPV vaccination rate remains just below the national average at 48% 
(Centers for Disease Control and Prevention, 2011).   
In retrospect, Texas Governor Rick Perry consistently supported his decision to 
utilize the executive order until it returned to the spotlight in 2011 in his run for the 
Republican party nomination for President of the United States.  In an interview during 
September 2011 he commented,   
I think anything that a state can do to fight cancer is a wise and a thoughtful  
approach.  Did I make an error in how I went about this?  Yes, I’ve readily  
admitted that I shouldn’t have used an executive order.  I should have had an opt  
in, and I should have worked through the legislative process (Stengel &  
Halperin, 2011). 
   
  35 
Despite his recent change in perspective, he still has not rescinded his support for HPV 
vaccination, only his executive order.  Time will determine if the brief highlight of his 
past as a result of his presidential aspirations is enough to rekindle the national debate 
that could lead to substantive public policy changes.   
Virginia and Washington, DC:  Success Through Legislative Process 
 Following the legislative failure in Texas, across the United States only Virginia 
and Washington, DC managed to pass legislation that included the HPV vaccine in 
school entry requirements.  The two locations benefited from the initial wave of public 
support, but avoided the controversy surrounding Texas’s executive order by utilizing the 
legislative process.  In April 2007, the General Assembly of Virginia passed a bill 81 to 
17 in the House and 40 to zero in the Senate requiring that all girls entering sixth grade 
receive the HPV vaccine.  To pass the bill, Del. Phillip Hamilton commented that, “We 
built in safeguards to make sure it was a cautions approach” (Smith, 2007).  The 
safeguards included scheduling the requirement to begin October 1, 2008, effectively 
delaying its initiation until the start of the 2009 school year, more than two years after the 
legislation was approved.  This two year delay gave parents ample time to become 
comfortable with and learn more about the requirement.  In addition to delaying the start 
of the school entry requirement, the legislation included an amendment by Governor 
Timothy Kaine, a Democrat, liberalizing the parental exemption option for the HPV 
vaccine.  Specifically, the amendment stated   
Because the human papillomavirus is not communicable in a school 
setting, a parent or guardian, at the parent or guardian’s sole discretion, 
may elect for their child not to receive the human papillomavirus vaccine, 
after having reviewed materials describing the link between the human 
papillomavirus and cervical cancer approved for such use by the board 
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(An Act to amend and reenact §32.1-46 of the Code of Virginia, relating 
to requiring the human papillomavirus vaccine, 2007).  
 
In what may be a reflection of people’s discomfort with the sexual transmission of 
HPV, Virginia differentiates the HPV vaccine from other required vaccines protective 
against diseases that are “not communicable in a school setting.”  To opt out of the 
hepatitis B vaccine, which became a requirement following the failure of a risk-based 
vaccination strategy, parents must sign a waiver.  To opt out of the HPV vaccine, no 
action is required.  The distinction, in practice, makes the HPV vaccine a 
recommendation for parents in Virginia rather than a requirement, but still allows females 
access to the funding and insurance coverage that accompany required vaccines.  
Shortly after Virginia passed their legislation, the Washington, DC city council 
also passed, by a vote of seven to three, an HPV vaccine requirement for girls entering 
sixth grade.  Like Virginia, the city council delayed the effective start date of the 
legislation until the 2009 school year to allow time for implementation, and like Virginia, 
the legislation included a very liberal opt out option, allowing parents to refuse HPV 
protection for their daughters, for any reason, by simply filling out a form. 
Both Virginia and Washington, DC succeeded in including the HPV vaccine in 
school entry requirements by passing legislation through state congressional bodies or 
through city council members elected by the public, rather than resorting to the unilateral 
executive order that backfired in Texas.  They appreciated the potential controversy that 
could result from the public’s discomfort with an issue linked to sexual activity and 
postponed the initiation of legislation to allow people time to become comfortable with 
the vaccine.  In addition, they expanded the opt out criteria so that parents may opt out 
for any reason, which differs from other immunizations that require a religious (in 48 
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states) or philosophic (in 19 states) exemption.  This relaxed opt out option appeased 
parents and advocates of individual rights over public health.  These concessions will 
likely result in lower HPV vaccination rates, as decreased complexity of opt out options 
results in increased numbers of parents opting out (Rota, et. al., 2000).  However, the 
policies allowed for the successful passage of publicly acceptable legislation that should 
improve access for much of the population and improve HPV vaccine acceptability 
among parents who may view school vaccines as standard.  The 2009 school year marked 
the start of the HPV vaccine school entry requirement in both Virginia and Washington, 
DC and the policies were carried out with little public fanfare.  Since then, legislation 
was introduced in 2010 in Virginia to overturn the requirement, but has remained in 
committee.  The impact of legislation on vaccination rates will be measured in the 
coming years.     
In conclusion, states influenced Gardasil® vaccination policy primarily through 
support, or lack of support, for school entry requirement legislation.  Because states, with 
the exception of Virginia and Washington, DC, chose not to include Gardasil® in school 
entry requirements, they passed along policy responsibility for vaccinating the public to 
the next level: individual health care organizations and providers.  Planned Parenthood 
Mid and South Michigan is one example of a health care organization that struggled to 
establish organizational policies in response to federal and state policies, described 
below.   
Health Care Organization Policy:   
The Case of Planned Parenthood Mid and South Michigan  
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Planned Parenthood has provided health care for females and males for over 90 
years (Planned Parenthood Federation of America, 2011).  Planned Parenthood Mid and 
South Michigan (PPMSM) is a Planned Parenthood affiliate serving 62,000 mostly young 
female patients annually in 15 health centers across mid and southern Michigan (Planned 
Parenthood Mid and South Michigan, 2010).  Planned Parenthood Federation of America 
(PPFA) oversees PPMSM and 83 other Planned Parenthood affiliates across the United 
States (Planned Parenthood Federation of America, 2011).  PPFA operates on the 
national level supporting women’s reproductive health through policy advocacy and 
education, while guiding local affiliates in the provision of evidence based health care at 
more than 800 health centers (Planned Parenthood Federation of America, 2011).   
When the HPV vaccine was first approved by the FDA in June 2006, Cecile 
Richards, President of PPFA was in Kalamazoo, Michigan and commented, “Planned 
Parenthood looks forward to making sure that this vaccine is accessible and available to 
young women everywhere in this country” (Meehan, 2006).  Despite its availability 
elsewhere, almost four years passed after Richards’ statement before the vaccine became 
available at PPMSM, on May 1, 2010, in two of its 15 health centers. 
Initially, the primary reason PPMSM chose not to carry Gardasil® was that they 
awaited the outcome of state policy development (M. Steuber, PPMSM Vice President 
for Medical Affairs, personal communication, October 2009).  PPMSM waited for the 
state legislature to pass school entry requirements that would effectively vaccinate the 
younger population who would later become PPMSM patients, eliminating the need for 
PPMSM to vaccinate.  The bill (SB1416) however, failed (State of Michigan 93rd 
Legislature, December 15, 2006, p. 3289-3291), as described below. 
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Michigan Policy History 
 The state of Michigan was the first state to propose legislation to include the HPV 
vaccine in school entry requirements.  In September 2006, SB1416 was introduced in the 
state Senate (State of Michigan 93rd Legislature, September 12, 2006, p. 2060), requiring 
all girls entering sixth grade to receive the HPV vaccine.  The bill was introduced by 
Republican Senator Beverly Hammerstrom (State of Michigan 93rd Legislature, 
September 12, 2006, p. 2060), recommended for passage by the Senate Committee on 
Health Policy (State of Michigan 93rd Legislature, September 19, 2006, p. 2166), 
supported by all 11 female senators (State of Michigan 93rd Legislature, September 20, 
2006, p. 2193-2195) and the female governor Jennifer Granholm (Heinlein, 2006), and 
passed 36 to one by the Republican run Senate (State of Michigan 93rd Legislature, 
September 20, 2006, p. 2193-2195).  When the bill was then sent to the Republican run 
House, the House Committee on Health Policy supported the bill, and the House initially 
supported the bill 58 to 45 on December 14, 2006 but then agreed to temporarily 
postpone consideration (State of Michigan 93rd Legislature, December 14, 2006, p. 3279-
3289).  Michigan requires bills to be passed by a majority of members elected, not a 
majority of members voting, so the next day, December 15, 2006, the bill failed to 
produce majority support from the full component of 110 legislators, with a final vote of 
53 legislators voting in favor and 48 opposing the bill (State of Michigan 93rd 
Legislature, December 15, 2006, p. 3289-3291).  Two legislators showed up late, missing 
the vote, and the remaining seven were absent (State of Michigan 93rd Legislature, 
December 15, 2006, p. 3289).   
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Opposition came from Republican lawmakers arguing in favor of parental control 
specifically, not necessarily against the HPV vaccine generally.  According to Republican 
Representative Kevin Elsenheimer,  
I am the father of an 11 year old daughter.  My wife and I may decide to have her 
receive the vaccine at some point in her future.  The vaccine clearly shows great 
promise - some have said it’s miraculous.  My no vote is premised upon a concern 
that the government is rushing to ‘correct a wrong’ that can be handled easily 
through a personal family decision to vaccinate (State of Michigan 93rd 
Legislature, December 14, 2006, p. 3280).   
 
Republican Representative David Robertson had similar comments.  “While I recognize 
the potential benefit of this, or any vaccine, I cannot support the mandatory aspect of this 
bill.  I believe this should be a matter of parental choice” (State of Michigan 93rd 
Legislature, December 14, 2006, p. 3281).   
 Michigan struggled with the public controversy fueled by the media, which the 
rest of the country was starting to experience.  If the excitement of Gardasil’s® potential 
health benefits overshadowed any opposition when it was first approved, Michigan 
newspaper headlines helped reverse the trend and created controversy.  Headlines like 
“Pre-sex Vaccine Draws Little Opposition - Panel Recommends Shots for Girls as Young 
as 9 to Prevent Cancer” (The Associated Press, 2006) and “Virginity Patrol not the only 
irrational ones in HPV debate” (Alberty, 2006) and later “Michigan May Force Girls to 
Get Vaccine” (Heinlein, 2006) fueled extremist views surrounding the vaccine and school 
entry legislation in the state.  Despite the media’s focus on the “controversy” surrounding 
a vaccine that protects against the effects of a sexually transmitted infection and its feared 
contribution to premarital sex, no record of the premarital sex argument was made in the 
Senate (State of Michigan 93rd Legislature, September 20, 2006, p. 2193-2195) or House 
(State of Michigan 93rd Legislature, December 14, 2006, p. 3279-3289) records.  
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Eleven variations of HPV vaccination legislation have been and continue to be 
considered in Michigan, including bills related to information dissemination and 
insurance coverage, most without proceeding beyond the designated committee and 
therefore not open to debate (National Conference of State Legislatures, 2010).  The only 
HPV vaccine related bill legislators managed to pass was HB5322 in May 2008 that 
required HPV vaccine information to be included with other vaccine information if a 
school district provides vaccine information (State of Michigan 94th Legislature, 2008).   
Planned Parenthood Mid and South Michigan Policy History 
Without the support of school entry requirements from the state, and with a new 
PPFA policy requiring that all Planned Parenthood health centers provide the HPV 
vaccine, PPMSM started to search for ways to carry the expensive vaccine.  One option 
utilized by similar organizations in other states was to depend on their state’s health 
department to provide vaccines free to health care providers.  Rhode Island, with the 
highest vaccination rates in the country (73%), offers this convenience (Centers for 
Disease Control and Prevention, 2011).  However, the Michigan Department of 
Community Health does not provide vaccines free to all health care providers.  Instead, 
they require that patients make a separate trip to the state facilities to receive Gardasil®, 
charging a fee of $15 per injection.  Therefore, low-cost vaccine is currently available 
from the state, but not accessible through PPMSM providers.   
Another option examined by PPMSM was reimbursement of the vaccine for 
patients with Medicaid.  However, Medicaid declined to reimburse PPMSM for 
Gardasil®, which they do for other providers, for unknown reasons (M. Steuber, PPMSM 
Vice President for Medical Affairs, personal communication, 2010).  This prevented any 
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Medicaid patient from receiving the HPV vaccine at PPMSM unless they were willing to 
pay over $500 out of pocket.   
Approximately 70% of the PPMSM population was uninsured in 2010 (Small & 
Patel, 2011), making the Merck Vaccine Patient Assistance program a possible source of 
financial support for many patients (Merck, 2011).  The Merck Vaccine Patient 
Assistance Program, available to uninsured individuals who meet certain eligibility 
requirements, necessitates that patients and providers complete an application form, fax it 
to the company for approval, and wait for a response.  If approved, the patient can receive 
the vaccine for free, and replacement vaccines are sent to the provider quarterly.  While 
time spent completing forms, faxing to the company, and waiting for confirmation would 
be a burden on both patients and providers, and its lack of weekend availability would 
limit its usefulness, it could be an option for reduced cost vaccine for some patients. 
Without an outside source of funding to pay for the vaccine, nor a source of free 
or reduced cost vaccine, nor even reimbursement for the vaccine in many cases, and an 
economic recession straining finances, cash-strapped PPMSM passed the cost of the 
vaccine on to their patients, limiting accessibility.  While the patient cost of most services 
provided at PPMSM is determined by an income-based sliding scale made possible by 
Title X federal funding, PPMSM determined the organization could not support the cost 
of the vaccine on a sliding scale (M. Steuber, PPMSM Vice President for Medical 
Affairs, personal communication, October 2009).  All patients would be charged $150 for 
each vaccine injection in addition to a $30 injection fee, regardless of income, for a total 
of $540 if the full three dose series was completed at PPMSM.  Even those utilizing the 
Merck Vaccine Patient Assistance Program would still have to pay the $30 injection fee, 
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three times, for a total of $90.  This sum is often more than the cost of the annual exam, 
which can be free for uninsured patients.  
On May 1, 2010, four years after the FDA approved Gardasil®, PPMSM stocked 
HPV vaccines at two health centers to pilot HPV vaccine administration, and expanded 
Gardasil® availability to all health centers in 2011.  In staff training for implementation, 
the cost burden of the vaccine was emphasized through oral presentation and power point 
slides, in conjunction with other aspects of Gardasil® administration.  Availability of the 
vaccine at these two PPMSM facilities improved rates of vaccination from 11% to 17% 
(Small & Patel, 2011). 
In summary, the PPFA requirement that all Planned Parenthood health centers 
make HPV vaccination available to patients by 2012 has not translated into substantially 
increased vaccination of Planned Parenthood patients in Michigan.  The current climate 
of political and financial constraints in Michigan raises major cost barriers to vaccine 
implementation at PPMSM.  Political pressure prevented passage of a school-entry 
requirement, pushing responsibility for attaining high vaccination rates onto health care 
organizations and providers.  For PPMSM, this clinic encounter level responsibility 
presented challenges, especially challenges around cost issues.  Overcoming these 
constraints is important to the thousands of 19 to 26 year olds served by this organization, 
with PPMSM being the only source of health care for many of these patients.  
The Future:  Impact of the Affordable Care Act 
This paper has so far discussed Gardasil®’s policy history at the federal, state, 
and health care organization levels.  The next step is to look to the future.  As the political 
landscape changes with each election, priorities shift and HPV vaccine policy may return 
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to the forefront of debate and consideration, or fade into the background again.  Much of 
the future of HPV vaccine policy remains unknown and will continue to change as new 
research emerges.  Books will be written and discussed analyzing the politics of HPV 
vaccination.  For example, see Wailoo, Livingston, Epstein, & Aronowitz, 2010.  
However, despite HPV vaccine policy constraints at the federal, state, and health care 
organization levels in the past, a change in policy at the federal level, specifically the 
passage of The Affordable Care Act, is the most likely policy influence modification for 
the near future.    
After months of political debate, a final vote of 220 to 207 in the House and 56 to 
43 in the Senate, and not a single Republican vote, President Barak Obama signed the 
Affordable Care Act into law on March 23, 2010.  The extensive law focuses mainly on 
health insurance reform, eliminating over time practices such as denying coverage for 
pre-existing conditions, cancelling coverage for people who become ill, and imposing 
lifetime limits on coverage.  The law has the potential to shape public policy’s influence 
on HPV vaccine uptake through three provisions: increasing the number of people with 
insurance, expanding insurance coverage for young adults until age 26, and increasing 
preventive care insurance coverage, including recommended vaccines and the preventive 
maintenance visits where immunization is often addressed, for all people. 
Increasing the Number of People with Insurance  
 Perhaps one of the most politically contentious pieces of the Affordable Care Act 
is the individual mandate for health insurance.  By 2014, the law will require uninsured 
individuals, approximately 32 million individuals, to purchase insurance.  The federal and 
state governments will assist uninsured individuals in purchasing insurance in two ways.  
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First, the law expands Medicaid coverage for about 16 million people by covering most 
individuals with incomes up to 133% of the federal poverty level.  Second, federal 
subsidies will help expand access to private insurance for middle-income families 
through insurance exchanges (The New York Times, 2011).   
 Because cost and insurance coverage are one of the strongest influences on HPV 
vaccine uptake (Conroy et al., 2009, Jain et al., 2009), universal insurance coverage will 
likely decrease much of the HPV vaccine cost burden faced by uninsured individuals, 
increasing HPV vaccine uptake, especially for those over the age of 18 who do not have 
access to Vaccines for Children coverage due to their age.  An example of this potential 
influence is the one state with universal health coverage currently- 66% of adolescents in 
Massachusetts have initiated HPV vaccination, one of the highest percentages in the 
country (Centers for Disease Control and Prevention, 2011).  Insurance coverage may not 
be the only influence on HPV vaccine uptake, but it does help. 
Because the individual mandate does not go into effect until 2014, however, 
ample time exists for this particular aspect of the Affordable Care Act to be rescinded.  
Across the country, 31 lawsuits from Republican governors and attorneys general in 26 
states are making their way through the court system seeking to overturn the law.  The 
lawsuits focus on the individual mandate, with opponents arguing that government cannot 
require individuals to engage in commerce by requiring them to purchase insurance and 
proponents arguing that individuals will inevitably consume health care and therefore 
should finance health care (Sack, 2011).  The final outcome, which has the potential to be 
decided by the Supreme Court, will determine how much influence the individual 
mandate will ultimately have on HPV vaccine uptake.    
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Expanding Coverage for Young Adults Until Age 26  
 Starting September 23, 2010 (with exemptions for existing insurance plans 
through 2014), young adults are eligible for coverage under their parents’ health 
insurance until age 26, regardless of marital status, student status, or dependency status 
(United States Department of Health and Human Services, 2010).  Young adults face 
unique difficulties in accessing insurance coverage.  Employment varies and access to 
employer-based health insurance is often limited while young adults start to establish 
themselves in the workforce.  As a result, 30% of young adults are uninsured, the highest 
rate of any age group (Center for Consumer Information and Oversight, 2010).  The 
intent of the Affordable Care Act is to reduce the number of uninsured young adults by 
allowing the group access to their parent’s health insurance.  As more people become 
insured, the cost burden of the HPV vaccine on individuals may be eliminated and more 
people will likely become vaccinated.   
Increasing Preventive Care Insurance Coverage  
 Starting September 23, 2010, new health insurance plans (with exemptions for 
existing insurance plans), are required to offer preventive services free of charge, without 
a co-payment or deductible (United States Department of Health and Human Services, 
2010).  This piece of the Affordable Care Act includes immunizations in general, and 
HPV vaccination specifically.  As described above, cost and insurance coverage in 
general do influence HPV vaccine uptake.  However, research on the effect of smaller 
costs specifically, such as co-payments, on HPV vaccine uptake is limited. 
Impact on Health Care Organizations 
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 The Affordable Care Act has the potential to increase HPV vaccine uptake by 
reducing the cost burden of the vaccine for many individuals through expanded health 
insurance coverage.  When insurance companies cover the cost of the vaccine for most 
individuals, the cost burden is almost eliminated for health care organizations, especially 
those serving a currently largely uninsured population such as PPMSM.  Organizations 
may be able to focus their limited resources on the remaining individuals not covered by 
the Affordable Care Act, such as immigrants or individuals covered under existing 
grandfathered insurance plans that are exempt from the requirements.  As the Affordable 
Care Act becomes fully implemented in 2014, researchers, politicians and organizations 
will begin to evaluate its success or failure in improving health care in the United States 
and influencing HPV vaccine uptake. 
 As demonstrated in this chapter, insurance coverage is not the only system 
influence on HPV vaccine uptake.  Public policy at the federal level, including vaccine 
approval, recommendation, and funding, and at the state level, including school entry 
requirements, influence health care organizations and individuals.  As discussed in the 
next chapter, Chapter Three, a variety of influences at the health care organization level 
may also be modified to improve HPV vaccine uptake in individuals.    
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Chapter Three  
Modifiable Influences on HPV Vaccine Uptake at The Clinic Encounter Level: 
A Literature Review  
 
 This literature review was conducted to identify modifiable influences on HPV 
vaccine uptake relevant to clinical practice.  The investigator electronically searched 
PubMed using the search term “hpv vaccine.”  The search was limited to humans and 
female participants, as routine recommendation for HPV vaccination is currently limited 
to females, and the search was limited to publications in English, as the journals reporting 
results in the United States are published in English.  The search was also limited to 
articles published between January 1, 2009 and June 1, 2011, the time period when 
researchers began publishing HPV vaccine uptake studies.  CINAHL was searched 
separately using the same search term and time limitations to identify any additional 
studies not available in PubMed.  The author also performed hand searches of reference 
lists of publications that surfaced in the electronic search and met the inclusion criteria, 
and added her own research manuscript, accepted for publication on June 20, 2011 in The 
Journal for Nurse Practitioners.   
Studies were included if they provided direct measurement of uptake (not simply 
intention to vaccinate) and used variables the investigator identified as modifiable in 
clinical practice (see results).  Studies were excluded if they examined variables unable to 
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be modified directly in clinical practice, such as race or ethnicity, age, education level, 
income, marital status, or number of previous hospitalizations.  Studies were also 
excluded if they were not conducted in the United States, in order to increase relevance to 
clinical practice within the United States.  Each study was analyzed to identify the main 
findings.  Similar variables from the main findings were grouped together to extract 
summary factors of modifiable influences at the clinic encounter level. 
 Of the 1074 articles identified through the electronic database search, a total of 
nineteen articles met the inclusion criteria. Table 3.1 summarizes the findings from these 
studies.  Six modifiable influences relevant to clinical practice were extracted from the 
studies (see Table 3.2). The six influences were: 1) cost and insurance coverage, 2) 
provider recommendation, 3) vaccination opportunity, 4) HPV and HPV vaccine 
knowledge, 5) vaccine safety concerns, and 6) HPV risk (including documented HPV risk 
factors or perceived HPV risk). 
Cost and Insurance Coverage 
 Cost and insurance coverage is potentially modifiable at the clinic encounter in 
that organizations may have access to resources for patients who cannot afford to pay.  
Cost and insurance coverage in general differs greatly between females younger than 19 
years of age, who are more often insured and may be eligible for free vaccines through 
the Vaccines for Children program, and females 19 and older who are less commonly 
insured and have limited access to vaccine-specific funding.  Of the seven studies that 
addressed cost and insurance coverage as influences on HPV vaccination, (Caskey, 
Lindau, & Alexander, 2009; Conroy et al., 2009; Dempsey, Cohn, Dalton & Ruffin, 
2010; Jain et al., 2009; Moore, Crosby, Young, & Charnigo, 2010; Schluterman, Terplan, 
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Lydecker & Tracy, 2011; Zimet, Weiss, Rosenthal, Good, & Vichnin, 2010), most found 
cost and insurance coverage to be a influence in the young adult age group.   
Across the eligible age range, in a longitudinal survey of 189 females 13 to 26 
year old, Conroy et al. (2009) identified insurance coverage for the vaccine as the 
strongest predictor of HPV vaccine initiation (OR 5.31, 95% CI 1.61-17.49).  
Demonstrating the difference between the two age groups, 27% of 18 to 26 year old 
females cited cost as a reason for foregoing vaccination, while only 10% of younger 
females ages 13 to 17 years cited cost as a barrier (Caskey et al., 2009).   
Among studies specific to young adults, who are therefore no longer eligible for 
the Vaccines for Children Program, in an analysis of the 2007 National Immunization 
Survey-Adult data, Jain et al. (2009) found having health insurance as one of the only 
variables associated with initiation (p<0.05).  In another study of 19 to 26 year old 
insured females, 24.4% cited uncertainty about insurance coverage as a reason for not 
vaccinating (Zimet et al., 2010).   
Even the type of insurance seems to have an effect on vaccination.  In a study of 
outpatient gynecologic clinics, 47% of the nine to 26 year old females who initiated the 
HPV vaccine series had public insurance compared to 28% with private insurance 
(p<0.01) (Schulterman et al., 2011).   This finding was replicated in young adults 
specifically, where having public insurance increased the likelihood of vaccination when 
compared to private insurance (OR 0.52, 95% CI 0.45-0.59) or no insurance (OR 0.47, 
95% CI 0.26-0.85) (Dempsey et al., 2010).  
One study evaluated the impact of eliminating cost as a barrier by providing a free 
vaccine voucher at a university health center.  This was the only study that provided an 
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intervention to evaluate the effect of cost as an influence.  As a result, 50% of the 
participants (n=209) utilized the voucher to initiate vaccination (Moore et al., 2010). 
Provider Recommendation 
 Perhaps the most clinically relevant factor that has repeatedly been shown to 
influence HPV vaccine uptake is provider recommendation.  Seven studies confirmed 
that discussing the vaccine and receiving a recommendation from a health care provider 
often results in receipt of the vaccine (Caskey et al., 2009; Conroy et al., 2009; Dempsey, 
Abraham, Dalton, & Ruffin, 2009; Gerend, Weibley, & Bland, 2009; Gottlieb et al., 
2009; Guerry et al., 2011; Rosenthal et al., 2011).  One survey of 19 to 26 year old 
females, in which all participants were insured, found even the strength of the physician 
recommendation mattered, with patients who perceived a stronger recommendation from 
their physician having a four times greater likelihood of vaccinating than those who 
perceived a weaker recommendation from their physician (Rosenthal et al., 2011).   
While less modifiable but still important to understand, the specialty of the 
provider can be influential.  One study of Kaiser Permanente’s immunization data found 
that having a Pediatrician as a primary care provider was correlated with vaccine 
initiation when compared to Family Medicine providers (RR 0.81, 95% CI 0.79-0.83) or 
Internal Medicine providers (RR 0.93, 95% CI 0.87-1.00) (Chao, Velicer, Slezak, & 
Jacobsen, 2010).  A larger study of clinic visit data confirmed the influence of provider 
specialty where Pediatric providers were positively correlated with HPV vaccination 
when compared to Family Medicine (OR 0.92, 95% CI 0.81-1.04) or Gynecology 
providers (OR 0.24, 95% CI 0.18-0.33) (Dempsey et al., 2010).  These findings are 
consistent with uptake among other vaccines, not just the HPV vaccine, showing 
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Pediatricians consistently outperforming other provider specialties in vaccine 
administration.   
Provider characteristics other than specialty may also influence vaccine uptake.  
Having a male primary care provider was inversely associated with vaccine initiation (RR 
0.92, 95% CI 0.91-0.93) when compared to female primary care providers (Chao et al., 
2010).  Also, one of the first studies to explore influences on mothers decisions to 
vaccinate daughters found that mothers who declined vaccination at a health care visit 
had more often seen someone other than their usual health care provider.  This supports 
the belief that the strength of the relationship between provider and patient also matters, 
and not just the provider specialty or gender (Dempsey et al., 2009).  No studies were 
found that have evaluated the influence of nurse practitioners on HPV vaccine uptake. 
Vaccination Opportunity 
 Four studies found that females with a recent health care visit were more likely to 
have received the HPV vaccine than those without a recent health care visit (Caskey et 
al., 2009; Chao et al., 2010; Dempsey et al., 2010; Reiter et al., 2010), as the health care 
visit serves as an opportunity to access the vaccine.  A total of 13% of parents 
interviewed in North Carolina cited the lack of a health care visit as the reason they had 
not initiated vaccination for their daughters (Gottlieb et al., 2009).  However, the 
frequency of health care visits did not seem to be associated with vaccination (Mathur, 
Mathur, & Reichling, 2010).  Females who attended an outpatient visit (Cook et al., 
2010) and females who attended a preventive maintenance visit (OR 5.18, 95% CI 4.64-
5.79) (Dempsey et al., 2010) were more likely to initiate HPV vaccination than those 
attending a problem focused visit.  This finding supports the understanding that 
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vaccination opportunity specifically, rather than health care visits generally, influence 
vaccination, as preventive maintenance visits are traditionally when vaccination status is 
addressed (Schaffer, Humiston, Shone, Averhoff, & Szilagyi, 2001). 
 The author’s own research showed that four years after the vaccine became 
available to the public, vaccine availability at the clinic visit increased vaccination from 
11.1% prior to health center availability to 17.0% after it became available at the health 
center (Small & Patel, 2011).    
HPV and HPV Vaccine Knowledge 
 Knowledge about HPV and HPV vaccines are often modifiable at the clinic 
encounter as health centers have the opportunity to educate patients and parents about the 
common virus and vaccine protection available.  Eight studies examined HPV and HPV 
vaccine knowledge, as well as the source of that knowledge, as an influence on 
vaccination (Brewer et al., 2011; Caskey et al., 2009; Gerend et al., 2009; Gottlieb et al., 
2009; Guerry et al., 2011; Licht et al., 2010; Mathur et al., 2010; Zimet et al., 2010).  The 
results were mixed of how important these influences are on vaccine uptake, although 
knowledge never dissuaded vaccination.  Differences may vary among parents of 
adolescents, whose are deciding whether or not to vaccinate their child, and young adults, 
who are often deciding to vaccinate themselves.   
Among studies of parents of adolescents, knowledge of the HPV vaccine (but not 
HPV) was correlated with uptake in a small (n=82) study of parents (t -3.214, p<0.01) 
(Gerend et al., 2009).  In an early survey of parents, 14% had not heard of the vaccine 
(13% had not seen a health care provider) and the most commonly cited (22%) reason for 
not initiating was the need for more information (Gottlieb et al., 2009).  This study was 
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conducted only a year after Gardasil® became available and only 10% of those surveyed 
had initiated vaccination.  Two later studies supported the finding that needing more 
information about the HPV vaccine decreased the likelihood of vaccine initiation (aOR 
0.08, 95% CI 0.04-0.2) (Guerry et al., 2011) and not needing more information increased 
the likelihood of initiation (aRR 0.41, 95% CI 0.22-0.76) (Brewer et al., 2011).   
Among young adults, in a study of 406 university females, participants who knew 
that HPV caused genital warts were more likely to be vaccinated (aOR 1.85, 95% CI 
1.20-2.93) (Licht et al., 2010).  Two years after vaccine availability, 31.7% of females 
reported lack of information about the vaccine as a reason for not initiating vaccination 
(Zimet et al., 2010).  
The source of vaccine information may also influence vaccine uptake across the 
eligible age range.  A large, nationally representative survey found that vaccinated 
females were more likely to identify health care providers as their source of HPV vaccine 
information (69%) than unvaccinated females (28%) and 77% of all participants 
identified their health care provider as the source of HPV information they trust most 
(Caskey et al., 2009).  This study did not differentiate types of health care providers.  One 
survey of 177 high school females in California asked about the source of HPV vaccine 
knowledge and found that learning about the HPV vaccine from a physician or nurse was 
associated with vaccination (Mathur et al., 2010).   
Vaccine Safety Concerns 
 Three studies indicated that vaccine safety concerns influence vaccine uptake 
(Dempsey et al., 2009; Gerend et al., 2009; Zimet et al., 2010).  A study interviewing 
mothers of 11 to 17 year old females who attended a recent health care visit found eight 
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of the 19 mothers of unvaccinated daughters cited safety concerns due to its recent 
availability as a reason for declining vaccination (Dempsey et al., 2009).  Even in 
mothers who chose to vaccinate, seven of 33 expressed concerns about safety, but felt the 
benefits outweighed the risks (Dempsey et al., 2009).  In 19 to 26 year old females less 
than two years after vaccine approval, participants reported the newness of the vaccine 
(35.4%) and side effect concerns (24.4%) as reasons for not initiating vaccination (Zimet 
et al., 2010).  In a survey also approximately two years after Gardasil® availability, 24% 
of parents indicated the vaccine would have to be on the market for more than five years 
before they would feel comfortable providing it for their daughter (Gerend et al., 2009).   
HPV Risk 
 Eight studies examined HPV risk as an influence on HPV vaccination, either 
through documented risk factors or risk perception (Caskey et al., 2009; Chao et al., 
2010; Cook et al., 2010; Dempsey et al., 2009; Gottlieb et al., 2009; Licht et al., 2010; 
Moore et al., 2010; Zimet et al., 2010).  Two studies examined clinical risk factors for 
HPV.  Chao et al. (2010) found in 18 to 26 year old females that risk factors for HPV, 
including history of sexually transmitted infections, abnormal Pap smears and oral and 
transdermal contraceptive use are associated with HPV vaccine uptake.  This study 
examined a mostly insured population and did not investigate why the association exists. 
Conversely, a study of university females found that sexual activity in the past 12 
months, a history of a Pap smear or abnormal Pap smear, or a history of a sexually 
transmitted infection was not associated with vaccination (Moore et al., 2010).   
Six of the studies examined HPV risk perception.  Mothers (n=52) who declined 
vaccination for their daughters cited low HPV risk as a contributing factor in their 
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decision, and those who chose vaccination protection for their daughters recognized high 
risk of HPV in their choice (Dempsey et al., 2009).  In a larger study (n=889), 12.6% of 
parents with unvaccinated daughters cited the belief that their daughter was not yet 
sexually active as a reason for not initiating the vaccine (Gottlieb et al., 2009).  Thirty 
percent of 13 to 26 year old females also reported their lack of sexual activity as a reason 
for not vaccinating (Caskey et al., 2009).  A study of Florida Medicaid patients 
(n=718,660) found sexual activity to be positively associated with vaccine initiation (OR 
1.19, 95% CI 1.15-1.24) (Cook et al., 2010).  However, another study of university 
females found that risk perception (Licht et al., 2010) had no association with 
vaccination.  In a study of 19 to 26 year old females (n=185), the most commonly cited 
reason for not initiating vaccination was the belief that they were in a monogamous 
relationship (Zimet et al., 2010).    
Discussion and Conclusions 
Because of the relatively recent availability of Gardasil®, research is still in the 
early stages of evaluating uptake.  However, a review of nineteen available studies 
exploring HPV vaccine uptake did reveal six potentially modifiable influences amenable 
to being addressed at the clinic encounter level: 1) cost and insurance coverage, 2) 
provider recommendation, 3) vaccination opportunity, 4) HPV and HPV vaccine 
knowledge, 5) vaccine safety concerns, and 6) HPV risk.  
Research on HPV vaccine uptake began to take place soon after vaccine approval 
in 2006 and began to appear in publications in 2009.  The studies reported a wide range 
of vaccine initiation, from 9% to 65%, which may affect specific findings, but clearly 
demonstrates that high vaccination rates are possible.  Research examining what is 
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working in those areas with 65% uptake is needed, and also what is preventing 
vaccination in those areas with 9% vaccination rates. 
HPV vaccine research has mostly focused on vaccine initiation, rather than series 
completion.  Four of the studies identified evaluated series completion (Cook et al., 2010; 
Dempsey et al., 2010; Moore et al., 2010; Schluterman et al., 2011).  Research on series 
completion is often difficult as accurate records of series completion can be difficult to 
obtain, and the minimum of six months between series initiation and completion may 
prohibitively prolong the duration of a study.  In addition, influences on series 
completion may vary from influences on series initiation.  While this literature review 
focused on initiation influences, future research should continue to expand to evaluate 
influences specific to series completion. 
Much of the research has focused on adolescents as patients and their parents as 
providers of consent, as vaccine initiation is recommended at age 11 to 12 years old.  
However, catch-up vaccination is recommended by the Advisory Committee on 
Immunization Practices for all females through age 26 (Centers for Disease Control and 
Prevention, 2007), which encompasses a young adult group that will still benefit from the 
vaccine but may experience very different influences when facing vaccination.  As 
adolescents transition into adulthood, they begin to make health care decisions without 
parental consent and often face fragmented health care delivery systems as they transition 
from pediatric providers to family, internal medicine, or reproductive health providers, 
and attend fewer preventive care visits (Rand et al., 2007).  Further research is needed 
that focuses on the differences between the 9 to 18 year old and 19 to 26 year old 
populations.  
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In addition, much of the clinical research has studied patients who are mostly 
insured, or are uninsured but under the age of 19 and therefore eligible for the Vaccines 
for Children program.  Vaccines for Children is a federally funded, state-administered 
program that pays for nearly half of the vaccines given to children in the United States.  
Young adults are not eligible for the Vaccines for Children program, leaving them with 
fewer cost coverage options for one of the most expensive vaccines on the market.  The 
19 to 26 year old age group may face unstable insurance coverage as they move through 
school, unemployment, or the initial years of adult employment.  Further research is 
needed that focuses on the uninsured population and ways to remove cost barriers.   
Much of the research has focused on settings in which vaccination is traditionally 
managed, such as primary care settings.  Reproductive health centers, which often serve 
as the primary source of health care for young adult females, especially healthy females 
with primarily reproductive health needs, have been overlooked as a possible alternative 
means of increasing HPV vaccine uptake.  Further research is needed that focuses on 
reproductive health centers as a means of improving HPV vaccination.   
One limitation across the HPV vaccine uptake literature is the number of studies 
using unpublished, untested, and therefore inconsistent measurement tools to evaluate 
variables and concepts.  Only one study reported reliability statistics for their surveys 
(Rosenthal et al., 2011), and no studies named the survey instruments used to allow for 
comparison across multiple studies and confirmation of reliability and validity.  
The findings describing the association of provider characteristics with HPV 
vaccine initiation are limited in that they cannot explain if Pediatricians themselves, for 
example, are more likely to discuss, recommend, and carry vaccines, as is the case with 
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other vaccines, or if relationships with Pediatricians have been more longstanding by 
adolescence thereby increasing trust and influence, or even perhaps if those patients 
seeing pediatricians are more amenable to vaccination. 
The literature on HPV risk as an influence on vaccination is limited, mostly 
focusing on risk perception rather than actual risk of HPV (Caskey et al., 2009; Cook et 
al., 2010; Dempsey et al., 2009; Gottlieb et al., 2009; Licht et al., 2010; Zimet et al., 
2010).  One study that examined HPV risk factors among young adult females did find an 
association between risk and uptake, which indicates there may be a useful application of 
HPV risk to improving vaccine uptake.  However, most of the studies reviewed 
demonstrate a gap in our understanding of the use of HPV risk as a means of improving 
HPV vaccine uptake, especially in the context of organizations with limited financial 
resources.  Many organizations with limited resources, such as Planned Parenthood Mid 
and South Michigan, use risk-based decision making to determine allocation of limited 
resources for services such as Pap smears and sexually transmitted infection testing.  
Further study is required to determine if risk can be used at reproductive health centers as 
a basis for targeting limited organizational financial resources to improve HPV vaccine 
uptake, making sure those with the most risk receive the most protection. 
Finally, because of the rapid changes occurring since the introduction of the HPV 
vaccine in 2006, the existing research may already be considered outdated.  Initial 
research at the time of vaccine availability demonstrated high acceptability of the vaccine 
across a variety of populations (Brewer & Fazekas, 2007), which has not translated into 
high vaccine uptake, preventing researchers from relying on acceptability research to 
develop predictors of HPV vaccine uptake.  Since then, even intention to vaccinate has 
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not been shown to be reliable predictor of HPV vaccine uptake, with one study showing 
only 38% of parents who intended on vaccinating their daughter having done so a year 
later (Brewer et al., 2011).  As a result, researchers will have to continue to study 
influences and predictors specific to uptake, without relying on acceptability or intention.  
Since its approval, the vaccination process is rapidly progressing from its initial stages of 
availability to a time when the health care system has had the opportunity to become 
knowledgeable about the vaccine, establish systems and mechanisms for its delivery, and 
incorporate it into routine care.  Nevertheless, we know that HPV vaccine uptake remains 
far below the Healthy People 2020 goal of 80% (www.healthypeople.gov), so much work 
remains.
